Small cell lung cancer (SCLC) accounts for approximately one fifth of all lung carcinomas, and chemotherapy remains the preferred treatment for patients with this disease.
New research suggests brain tumor patients who take the antiepileptic drug valproic acid on top of standard treatment may live a few months longer than people who take other kinds of epilepsy medications to control seizures.
When I started to work at the EORTC Headquarters Quality of Life Department in March 2008, I thought that it would be nice to spend one year gaining experience and studying cancer from another point of view. Three years (and a couple of rainy days) later, I’m still in Belgium and I can confirm I made the right choice.
My fellowship has been renewed twice and during these three years I have learnt a lot, had wonderful experiences, met very nice people, gained new knowledge and hopefully shared the knowledge I already had.
The Innovative Medicines Initiative (IMI), a unique partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA), recently announced that the QuIC-ConCePT (Quantitative Imaging in Cancer: Connecting Cellular Processes with Therapy) consortium has been awarded a grant to study imaging biomarkers (IBs) for anticancer drug development.
The primary intent of this website is the communication of clinical cancer research with oncologists and health professionals in the field, but it is recognized that the information presented here might also be of interest to patients, charities, funding organizations and the general public.
Results of the EORTC 62072 PALETTE (PAzopanib ExpLorEd in SofT-Tissue Sarcoma) trial presented at the 2011 Annual Meeting of the American Society for Clinical Oncology demonstrated a statistically significant improvement in the time to first occurrence
Posted on 28 April 2011
Lung cancer, accounting for 18.2% of cancer deaths in the world, is the most common cancer worldwide in both incidence and mortality for men and women. Not only is the incidence rate high, but the survival rate is low: the one year survival rate of lung cancer patients is only 42%, and the five-year rate is 16%.
Posted on 28 April 2011
